Comparison of haploidentical transplantation and single cord blood transplantation for myelofibrosis

Kazuki Sakatoku,Makoto Murata,Yutaka Shimazu,Naoyuki Uchida,Satoshi Yoshihara,Yasufumi Uehara,Satoshi Takahashi,Hikaru Kobayashi,Haruyuki Tanaka,Nobuaki Nakano,Fumihiko Ishimaru,Tatsuo Ichinohe,Yoshiko Atsuta,Tokiko Nagamura-Inoue,Hirohisa Nakamae
DOI: https://doi.org/10.1038/s41409-024-02244-z
2024-02-21
Bone Marrow Transplantation
Abstract:Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelofibrosis (MF) [1]. In the absence of an HLA-matched donor, HLA-haploidentical HCT (haplo-HCT) and unrelated cord blood transplantation (CBT) provide access to potentially life-saving therapies; this is because donors are rapidly available and the timing of transplantation is more flexible. However, the preferred choice between CBT or haplo-HCT for MF patients remains unclear. This multicenter retrospective study analyzed clinical data obtained from the Unified Management Registry sponsored by the Japanese Society for Transplantation and Cellular Therapy (JSTCT). We compared the outcomes of 77 patients with MF who underwent haplo-HCT ( n = 27) or CBT ( n = 50) as first HCT between 2003 and 2019. The study was approved by the data-management committee of the (JSTCT), the Institutional Review Board of Osaka Metropolitan University, and all participating centers, and was conducted in accordance with the principles set down in the Declaration of Helsinki.
oncology,immunology,hematology,transplantation
What problem does this paper attempt to address?